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KAJIAN PERBANDINGAN MENGGUNAKAN KAEDAH PENGIONAN 
ELEKTRON DAN PENGIONAN KIMIA SPEKTROMETRI JISIM UNTUK 
PENGESAHAN DAN KUANTIFIKASI DADAH PERANGSANG DALAM 
AIR KENCING 
 
ABSTRAK 
 
 
Prosedur analisis untuk mengesan dadah perangsang dalam air kencing 
menggunakan gas kromatografi-spektrometri jisim (GC-MS) merupakan satu 
cabaran yang perlu dihadapi oleh makmal anti-doping. Penggunaan reagen terbitan 
untuk kompoun sasaran akan memberikan bentuk kromatogram yang lebih baik, 
mengurangkan polariti kompoun dan meningkatkan ciri-ciri kromatografi gas, 
menyediakan pemisahan yang baik dan menghasilkan spektrum jisim yang 
berintensiti tinggi untuk kedua-dua pengenalpastian dan analisis kuantitatif, sekali 
gus meningkatkan pengesanan sesuatu kompoun. Tindak balas sililasi, asetilasi dan 
alkilasi adalah kaedah terbitan yang paling berkesan dan biasa digunakan untuk GC-
MS. Kajian ini memberi tumpuan kepada lima dadah perangsang terlarang daripada 
senarai dadah terlarang WADA iaitu Amfetamina, Metamfetamina, Efedrina, 
Metilefedrina dan Katina. Apabila kompoun ini diterbitkan dengan pelbagai jenis 
reagen terbitan, had pengesanan boleh diturunkan dengan ketara. GC-MS secara 
tradisionalnya menggunakan kaedah pengionan elektron yang  menghasilkan produk 
ion serpihan  jisim yang rendah; ini membuatkan  pengesahan kompoun menjadi 
sukar. Apabila kompoun terbitan dianalisa menggunakan pengionan kimia (CI) 
dalam GC-MS, ion berproton [M + H]+ serta [M +29]+ dan [M+41]+ akan 
diperolehi dan boleh digunakan sebagai ion pengesahan. Kajian ini menunjukkan 
bahawa penggunaan TMSTFA sebagai reagen terbitan dan analisis menggunakan 
xvii 
 
kaedah pengionan kimia (CI) boleh memenuhi kriteria pengenalan   kualitatif   
selaras dengan kriteria WADA.  Dalam kajian ini, had pengesanan bahan-bahan 
ambang iaitu efedrina, metilefedrina dan katina, didapati 50% lebih rendah daripada 
paras ambang yang ditentukan oleh WADA; had pengesanan efedrina dan 
metilefedrina adalah masing-masing 39.0 ng/mL dan 1250 ng/mL manakala bagi 
katina, had pengesanan adalah 39.0 ng/mL.  Nilai ambang yang ditetapkan oleh 
WADA sebaliknya adalah lebih tinggi, 10 µg/mL bagi efedrina dan metilefedrina, 
dan 5 µg/mL bagi katina. 
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COMPARATIVE STUDY OF THE UTILITY OF ELECTRON IONIZATION 
AND CHEMICAL IONIZATION MASS SPECTROMETRY FOR 
CONFIRMATION AND QUANTIFICATION OF STIMULANTS IN URINE 
 
 
ABSTRACT 
 
 
An analytical procedure for the detection of stimulants in urine using gas 
chromatography-mass spectrometry (GC-MS) is one of the analytical challenges 
facing anti-doping laboratories. The use of derivatising reagents for the target 
compounds will provide better peak shapes, reduce the polarity and enhance the gas 
chromatographic properties, providing a good separation and mass spectra with high 
abundance for both identification and quantitative analysis, thus enhancing the 
detectability of a compound. Silylation, acylation and alkylation reactions are the 
most effective and common derivatization methods that are used for the GC. This 
research was focused on five banned stimulants from the WADA prohibited list 
which were amphetamine, methamphetamine, ephedrine, methylephedrine and 
cathine. When these compounds were derivatised with various derivatising reagents 
the limits of detection can be lowered considerably. Traditional GC/MS using 
electron impact ionisation suffers from product of low mass fragment ions making 
confirmation of these analytes difficult. When these derivatised compounds were 
analysed using chemical ionisation (CI) in the GC-MS, the protonated ion [M+H]
+ 
as well as the [M+29]
+
 and [M+41]
+ 
ions were obtained to be used as confirmatory 
ions. This research showed that using two steps derivatization by MSTFA followed 
by MBTFA and analysis using chemical ionisation (CI) can fulfil the identification 
criteria for qualitative identification of compounds in line with the WADA criteria. 
In this research the LOD of the threshold substances; ephedrine, methylephedrine, 
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cathine, were lower than 50% of the WADA threshold concentration; LOD of 
ephedrine and methylephedrine were 39.0 ng/ml and 1250 ng/ml and for cathine the 
LOD was 39.0 ng/ml. The WADA threshold on the other hand were much higher,  
10µg/ml for ephedrine and methylephedrine and 5µg/ml for cathine.   
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CHAPTER 1 
INTRODUCTION 
1.1 Background 
 
 
 In the field of sport, the analytical challenge facing anti-doping laboratories is 
to detect the presence of  forbidden substances through the analysis of body fluids. 
One  of the analytical techniques that has been successfully shown to provide 
evidence of abuse is gas chromatography coupled to mass spectrometry (GC/MS) 
(Hemmersbach & de la Torre, 1996). 
 
 GC/MS is useful tool for chemical analysis, especially when used together 
with MS/MS have more recently been introduced. MS/MS has the advantage of 
identifying compounds by first;  selecting an ion of single mass to charge (m/z) value 
in the first MS, then subjecting it to fragmentation using specific collision energy 
following which the m/z ions in the second MS were detected (Huestis & Smith, 
2006). 
 
Some compounds cannot be analyzed by a particular method in GC/MS 
because of the following: they are not amenable to the analytical technique as they 
cannot be volatilized or they are not stable under these technical conditions. The 
chemical structure of these compounds has to be modified to enable analysis by the 
desired technique. The interaction between the compounds themselves or between 
the compounds and the column in some analysis can lead to poor peak resolution or 
unsymmetrical peaks which makes the identification of the peak difficult. Sometimes 
a very small amount of compound in a complex matrix need to be analysed, so it is 
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important to extend the range of detectability to very low levels either by improved 
detector design or increasing the detectability of the compound itself. Some of these 
problems may be solved through the use of derivatization techniqes. 
  
Derivatization plays an important role in gas chromatography (GC) through the 
following ways: it increases the analyte volatility and improves the chromatographic 
characteristics by decreasing the polarity in addition to increasing the detector 
sensitivity of the analyte (Robert J, 1999). At the same time derivatization will not 
change the arrangement of the structure during derivative formation; in addition there 
will be no sample losses during the reaction and it will not interact with the GC 
column. Most derivatives help to replace active hydrogen atom attached to the 
compound with the one which is more stable and less polar. The derivative of the 
original analyte will show more volatility and more symmetrical peaks by reducing 
the peaks tailling. Different types of derivatizing reagent can be used in GC/MS but 
some are preferred for certain  types of detectors; for example trimethylsilyl and tert-
butyldimethylsilyl derivatives are preferred for GC/MS with positive ion electron 
impact (EI) detection as it increases the detectability of the compounds and it is 
easily formed. Fluorinated derivatives are formed in cases where negative ion 
chemical ionization mass  spectrometry (NICI/MS) with electron capture detector 
(Robert J, 1999). 
 
This research will focus on five banned stimulant from the World Anti Doping 
Agency WADA prohibited list which are: amphetamine , methamphetamine , 
ephedrine , methyl ephedrine and cathine derivatized with five different derivatising 
reagents. These are: N-Methyl-N-trimethylsilyltrifluoroacetamide activated I 
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(MSTFA ACTIVATED I), N-Methyl-bis(trifluoroacetamide) (MBTFA),1 
(trifluoroacetyl)imidazole (TFAI), pentafluoropropionic anhydride (PFPA), 
heptafluorobutyric anhydride (HFBA) and two steps derivatization by MSTFA 
followed by MBTFA. 
 1.2 Research Objectives 
 
The measurable objectives of this study are listed as follows:  
 
1. The study will investigate various derivatization reagents that can be used for 
functional groups on the molecular structures of the stimulants 
(Amphetamine, Methamphetamine, Ephedrine, Methyl ephedrine and 
cathine) to achieve the limits of detection in the range of 50-100 times better 
than traditional GC/MS analysis. 
 
2. Conduct analysis using the various derivatives in both Chemical ionization 
(CI) and Electron ionization (EI) in GC-MS to determine which of these 
techniques will achieve the best sensitivity with the different types of the 
derivatising reagents.  
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CHAPTER 2 
Literature review 
2.1 Stimulants  
 
Stimulants refer to a class of drugs that include psychomotor stimulants, 
central nervous system stimulants and sympathomimetic amines. These compounds 
activate the body mentally and physically by increasing the heart and breathing rates 
(Colmain & Council, 2010) (Lu et al., 2010). As a result they help in reducing 
tiredness and muscle fatigue and increase stamina, especially in training and 
competition among athletes. 
 
On the other hand, stimulants have adverse effects of which addiction is the 
most serious but it also causes hypertension, anxiety, irregular heartbeat, and stroke 
which can lead to death (Lu et al., 2010). There are exceptions in that some 
stimulants are included in the 2012 monitoring program of WADA prohibited list  
because they are used as a medication. An example is adrenaline which is used in the 
preparation of local anesthetic substances such as xylocaine. There are many other 
types of stimulants which are not prohibited, if their concentration in the urine does 
not exceed a certain specified limit. For example , cathine, ephedrine, methyl 
ephedrine and pseudoephedrine are nonprohibited stimulants when their 
concentrations are less than 5, 10, 10 and150 µg/mL respectively (Colmain & 
Council, 2010). 
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2.2      Amphetamine 
 
Amphetamine is one of the major types of central nervous system (CNS) 
stimulants (George, 2000) which was first synthesized in Germany in 1887. It has 
been used during the World War II as a stimulant. Amphetamine is also considered 
as a medication in different clinical cases such as shock, encephalitis, postural 
hypotension and obesity (Greene et al., 2008). 
 
2.2.1    Chemical and physical structure of amphetamine  
 
The chemical name for amphetamine is α-Methylphenethylamine with the 
formula (C2H13N) (Foltz et al., 1980). The chemical structure is shown in Figure 2.1. 
  It is one of the derivatives of phenylethylamines which are similar to 
adrenaline in composition. If the ethyl chain is modified by replacement of various 
hydrogen atoms which can occur either at the alkyl carbon atoms, aromatic ring or 
terminal amino nitrogen group, the resulting compound can give different clinical 
effects (Greene et al., 2008).   
   
Amphetamine physically is a colorless liquid with a boiling point of 200ºC to 
203ºC (Clarke, 1986); it is soluble in acid, alcohol and ether but only slightly soluble 
in water (Foltz et al., 1980). 
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Figure 2.1 Chemical structure of Amphetamine (Sukkwan, 2006) 
 
2.2.2    Amphetamine metabolism  
 
Amphetamine is metabolised to several metabolites through the following 
pathways: deamination to produce phenylacetone which is further oxidized to 
benzoic acid. It also undergoes β-hydroxylation to produce norephedrine and 
hydroxylation to produce o-hydroxynorephedrine. In Figure 2.2, the metabolic 
pathway of amphetamine is illustrated (Sukkwan, 2006). 
 
Amphetamine is excreted in the urine within 20 minutes of administration 
(Sukkwan, 2006) as the following; 30% as unchanged drug, 3% as p-
hydroxyamphetamine, 3% as phenylacetone, 20% as benzoic acid and 5% as p-
hydroxynorephedrine  (Foltz et al., 1980) . Excretion of the unchanged drug depends 
on the urinary pH. In alkaline urine, 45% of the dose is excreted within 24hr and 2% 
of it as unchanged drug. On the other hand in acidic urine, 78% of the dose is 
excreted within 24hr and 68% as the unchanged drug (Sukkwan, 2006) . 
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2.2.3 Amphetamine properties and effects  
 
Amphetamine exerts the following effects: increased stamina, excitement, 
concentration and mental aptitude, increase in physical  energy and decreased 
appetite (George, 2000; Greene et al., 2008). Because of these properties, most of the 
amphetamine abusers are students undergoing examination, drivers who travel long 
distances and athletes  that require enhanced performance and endurance (Kintz et 
al., 1989). 
 
The major side effects that appear in the amphetamine abusers are confusion, 
delirium, palpitation, sweating,  hypertension, tachycardia and joint and muscle pain 
but there are some effects that  depends on the drug dosage; these include  anxiety, 
irresponsible behavior, restlessness  and depression (George, 2000). 
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Figure 2.2 Metabolic pathway of amphetamine, adapted from (Sukkwan, 2006) 
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2.3      Methamphetamine   
 
 
Methamphetamine is one of the more popular central nervous system (CNS) 
stimulants; it is a derivative from the class of amphetamines and its first large scale 
production took place in 1919 in Japan, it is popularly known as crystal meth, ice, 
speed and crank (Logan, 2002). 
 
2.3.1   Chemical and physical structure of methamphetamine 
 
Methamphetamine is the common name for N-methyl-1-phenylpropan-2-
amine with chemical formula of C10H15N (Logan, 2002). The chemical structure is 
illustrated in Figure 2.3. 
 
 
 
 
 
 
Figure 2.3 Chemical structure of methamphetamine (Foltz et al., 1980) 
 
 
 
 
Methamphetamine is produced via chemical synthesis to produce either the 
powder or crystal form of the drug. This will also contain small amounts of 
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intermediate chemical compounds such as ephedrine and pseudoephedrine. These 
compounds like amphetamine, possess a chiral centre  (Inoue et al., 2008) . Therefore 
methamphetamine can exist in the form of two optical isomers which are; D-
Methamphetamine and L-Methamphetamine ( Figure 2.4) These isomers are similar 
in chemical reactions, melting points and solubility but they  differ in smell and their 
pharmacological effects in the body because they fit into the receptors in different 
ways (Freye & Levy, 2009). 
 
 
 
 
  
 
        D-methamphetamine                                                  L-methamphetamine 
 
Figure 2.4 Molecular structures of both optical isomers of methamphetamine 
differing only in their ability to rotate plane polarized light; adapted from (Homer et 
al., 2008). 
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physically Methamphetamine is colorless and odorless, with a boiling point 
of 212ºC (Foltz et al., 1980). Pure methamphetamine has an oily texture which 
makes it insoluble in water but with good solubility in ether and ethanol. On the 
other hand, methamphetamine hydrochloride which is the salt form of 
methamphetamine, is soluble in water, ethanol and chloroform but insoluble in ether; 
the melting point of the salt is 173ºC (Freye & Levy, 2009). 
 
2.3.2  Methamphetamine Metabolism 
  
Methamphetamine is metabolized in the liver by three mechanisms: (1)  
N-demethylation to produce amphetamine, catalyzed by cytochrome P4502D6  
(Figure 2.5.a), (2) aromatic hydroxylation via cytochrome P4502D6 to produce 
primarily 4-hydroxymethamphetamine (Figure 2.5.b.) and (3) β-hydroxylation to 
produce norephedrine (Figure 2.5.c) (Cruickshank & Dyer, 2009). It must be 
considered at this point that there are many drugs that are metabolized to both 
amphetamine. For example ; benzphetamine (didrex), an anti-obesity drug (Cawley 
& Rizzo, 2005), is metabolized to desmethylbenzphetamine but also to D-
methamphetamine and amphetamine; Deprenyl, a drug used in the Parkinson's 
disease, is unusual in that it is metabolized to L-amphetamine and L-
methamphetamine; Famprofazone (Gewodin), used as a painkiller and an antipyretic 
drug, is metabolized to D- and L-methamphetamine and amphetamine. Hence, 
analysis of the enantiomers together with testing of the ingested drug metabolites, 
taking into account the amphetamine and methamphetamine concentrations, will help 
to verify the source of the measured drug (Logan, 2002).   
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Figure 2.5 Chemical structures of amphetamine metabolites produced in the liver via: 
(a) N-demethylation, (c) aromatic hydroxylation and (b) β-hydroxylation (Foltz et 
al., 1980) 
 
 
Methamphetamine is excreted in urine depending on the pH; in normal urine 
pH (6-8), 37-54% of the dose of methamphetamine is excreted as the parent drug 
with 4-7% as D-amphetamine (Beckett & Rowland, 1965)  
 
2.3.3   Clinical effects of Methamphetamine  
 
General immediate effects of the methamphetamine include euphoria, 
decreased appetite, increased energy and the effect may remain for 4 to 12 hours 
depending on the dose (Wilkins, 2002). 
 
  Methamphetamine can be used in different ways either by snorting, injecting, 
smoking or by oral administration (Wilkins, 2002). Some symptoms are associated 
with the route of administration. For example, taking methamphetamine 
intravenously may lead to antisocial behavior and speeds up symptoms of 
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schizophrenia. The “rush” or “flash” which takes a few minutes is described as 
extremely pleasurable; the latter can be due to smoking of amphetamine while the 
oral consumption or snorting of amphetamine produce only euphoria but not a rush. 
Other symptoms that appear in case of addiction of methamphetamine are fatal lung 
and kidney disorder, decreased immune system, brain and liver damage and stroke 
(Freye & Levy, 2009) 
2.4 Ephedrine and Methyl ephedrine   
 
Ephedrine is one of the natural alkaloid extracted from plant of the genus 
Ephedra (Amare et al., 2011) which is one of the traditional herbs used by the 
Chinese for medication purposes for more than 5000 years. Although Ephedra has 
six optically active alkaloid which are: (+)-pseudoephedrine, (-)-ephedrine, (-)-N-
methyl ephedrine, (+)-N-methyl pseudoephedrine, (-)-norephedrine, and (+)-nor 
pseudoephedrine, the major  alkaloid (-)-ephedrine comprises 30-90% of the total 
amount and is considered one of the first alkaloid that was  extracted from Ephedra 
(Abourashed et al., 2003). 
 
2.4.1   Chemical and physical properties of ephedrine and methyl ephedrine  
 
 Ephedrine and methyl ephedrine molecular weights are 165 and 179 
respectively with chemical formula C10H15NO  and C11H17NO respectively Figure 
2.6 shows the chemical structure of ephedrine and methylephedrine.  
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 Ephedrine is characterized physically as having a waxy solid texture which 
comes as colorless crystals, granules and decomposed gradually when exposed to the 
light. It has a melting point of 40
°
C to 43
°
C and it is soluble in water, chloroform and 
ether but less soluble in ethanol while methylephedrine is soluble in chloroform and 
ether (Tilstone & Stead, 1986). 
 
               
             Ephedrine                                                Methyl-ephedrine      
 
Figure 2.6 Chemical structures of Ephedrine and Methyl-ephedrine; adapted from  
(Spyridaki et al., 2001). 
 
                          
2.4.2   Ephedrine sources and synthesis  
 
  
Ephedrine can be obtained via three methods as shown in Figure 2.7; the first 
method is through the production of natural ephedrine from Ephedra plants. In this 
method, the composite output is of natural origin and this is what is applied in the 
ephedrine factories in china. The second method is a semi-synthetic process which is 
through the fermentation of sugar followed by amination and  this is commonly 
found in India, in this method the nitrogen source is methylamine (CH3NH2), which 
is added in step two of the manufacturing process.. The third method is chemical 
synthesis  by bromination of propiophenone followed by amination (Makino et al., 
2007). 
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2.4.3   Chemical and pharmacological effects of ephedrine  
 
Ephedrine and pseudoephedrine are both classified under sympathomimetic 
alkaloids because of their direct effects on the sympathetic nervous system; this is 
because it acts on the α and β-sympathetic receptors on the cell membranes   found 
on most body organs such as heart, lungs and surrounding blood vessels. 
These receptors  are sensitive to ephedrine and norepinephrine (Powers, 2001) 
resulting in the increase in heart rate, peripheral vasoconstriction, bronchodilation 
and central nervous system stimulation. For this reason, ephedrine has  many 
therapeutic uses such as for weight loss (Abourashed et al., 2003), treatment of 
bronchial asthma and as spinal anesthesia (Amare et al., 2011). 
 
Pharmacological effects that can be associated with ephedrine and considered 
to be minor side effects are palpitation, restlessness, headache, insomnia and anxiety. 
On the other hand, there are serious side effects which include severe hypertension, 
irregular heartbeat, mental disorder, hepatitis, stroke and intracranial hemorrhage 
(Powers, 2001) 
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Figure (2.7) Production schemes for ephedrine adapted from Makino et al., 2007. 
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2.5    Cathine  
  
 Cathine or  D-norpseudoephedrine, Figure (2.8), is one of the active alkaloids 
of Khat (Feyissa & Kelly, 2008), a plant used in eastern Africa and southern Arabia; 
the fresh leaves is chewed and the dried form is consumed as tea (Zelger et al., 
1980). Cathine is produced as a result of enzymatic conversion of cathinone which is 
one of the other active alkaloid of Khat. During khat maturation it is also formed by 
the reduction of cathinone during drying and storage of Khat.  
 
2.5.1   Chemical and physical structure of cathine  
 
 
Cathine is the popular name for (+) norpseudoephedrine with chemical 
formula of (C9H13NO); the molecular weight is 151.2 and the melting point of the 
crystal form of cathine is 77
 
- 78ºC and it is soluble in ethanol, chloroform and ether 
(Clarke, 1986). 
  
2.5.2  Clinical effects of cathine   
 
 A study (Mwenda et al; 2004) has shown that cathine may affect the 
reproductive system in reducing the utero placental blood flow, maternal weight gain 
and maternal myoendometrial blood flow. On the other hand cathine may increase 
placental vascular resistance and maternal blood pressure (Mwenda et al., 2004).  
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Figure 2.8 Chemical structure of norpseudoephedrine adapted from (Marais & 
Laurens, 2009) 
 
2.6      Derivatization  
 
Derivatising reagents are chemical compounds that are  used to replace the 
unstable hydrogen atom attached to the heteroatom (Robert J, 1999) in functional 
groups such as hydroxyl, carboxylic acid and amines (Segura et al., 1998) with less 
polar and more stable group. This will increase the volatility of the analyte which 
leads to improved chromatographic characteristic that can occur either by decreasing 
the analyte polarity or increasing the detector sensitivity (Robert J, 1999) . 
 
2.6.1   Application of the derivatising reagents in Gas Chromatography Mass 
Spectrometry (GC-MS) 
 
When target compounds are injected into the Gas chromatograph, the results 
of the analysis must be based on the mass spectra criterion which sometimes requires 
improvement through derivatization reagents.  One of these criteria is better peak 
shapes without what is known as ghost peaks which can be formed as a result of 
column adsorption especially for thermo labile and polar compounds. Using the 
derivatising reagents will reduce the polarity and enhance the gas chromatographic 
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properties.   Another criterion that is taken into account is the separation of closely 
related compounds which cannot be separated in the underivatized form; derivatising 
reagents can help in providing a good separation and mass spectra with high 
abundance for both identification and quantitative analysis which are usually based 
on monitoring of at least three ions. Derivatising agents also enhances the 
detectability of a compound. Using derivatising reagents can provide high electron 
affinity groups such as halogen atoms which increase the ionization efficiency in 
negative chemical ionization (NCI) (Segura et al., 1998),  thereby reducing the limit 
of detection of the particular compound . 
 
2.6.2    Disadvantages of derivatising reagents in Gas chromatography mass 
spectrometry (GC-MS)  
 
 Formation of multiple derivatives is an indicator of unsuccessful 
derivatization and this can occur because of incomplete reaction of derivatization of 
polyfunctional compounds. Other obstacles that may be faced during derivatization is 
the side products of the derivatization reaction and its effect on the stability of the 
derivatives formed.  For example the halogen acids that may be formed through 
acylation with anhydrides and acyl halides can produce dehydration or enolization 
which are the side reaction. In this case, neutralization is required (Segura et al., 
1998). 
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2.6.3   Types of derivatives useful in GC 
  
Prior to analysis of the compounds with functional groups that contain active 
hydrogens ( OH, COOH, SH and NH), they should be treated with an appropriate 
derivatising reagent to avoid reduction of volatility and thermal instability which 
may lead to the interaction with fused silica or the stationary phase resulting in a 
broad peak (Danielson et al., 2000). Silylation, acylation and alkylation reactions are 
the most effective and common derivatization methods that are used for GC 
(Danielson et al., 2000). 
 
2.6.3.1   Silylation  
 
Silylation is one of the most commonly used derivatization procedure for GC-
MS analyses and it is formed by the displacement of active proton in OH, NH or SH 
groups by an alkylsilyl group. The functional groups that are present in an organic 
compound   can be converted to silyl ester or ether but the ease of formation of silyl 
derivatives differ from the most to the least efficient according to the following: 
alcohol > phenols > carboxylic acids > amines > amides. 
The most common silylation derivatising reagent which is used in GC-MS 
analyses are the TMS-amides; these include N-methyl-N-trimethylsilyl-
trifluoroacetamide (MSTFA) (Figure.2.9) and N-O-bis-trimethylsilyl-
trifluoroacetamide (BSTFA) (Figure.2.9). Because of their high volatility and 
silylating power, these derivatising reagents has been widely used for analytical 
purposes. Trimethylsilylimidazole (TMSI) (Figure.2.9) also has strong silylation 
affinity for carboxyl and hydroxyl groups but not for amino groups. Tert-
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Butyldimethylsilyl (TBDMS) derivatives are also used to increase the stability and to 
give good mass spectrometric fragmentation but the disadvantage of TBDMS is the 
difficulty they present for the derivatising of sterically hindered groups (Segura et 
al., 1998). The general reaction for the formation of trialkylsilyl derivatives is shown 
in scheme 2.1  
 
 
 
Scheme 2.1: General reaction mechanism for the formation of trialkylsilyl 
derivatives for trimethylchlorosilane, X = Cl, adapted from (Orata) 
 
 
A study published in 2009 (Bertrand R.Brunet et al., 2008) reported the use 
of BSTFA with trimethylchlorosilane (TMCS) as a derivatising reagent to prove that 
the method  permits the simultaneous quantification of methadone, and heroin, 
cocaine and metabolites in human sweat (Brunet et al., 2008). BSTFA and N-methyl-
n-(tert-butyldimethylsilyl)trifluoroacetamide (MTBSTFA) are required as 
derivatising  reagents to convert ethanolamines which result from degredation of 
nitrogen mustard to (TMS) and (TBDMS) esters.  (Kenar & Alp, 2011). 
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Figure 2.9  Chemical structure of BSTFA, MSTFA and TMSI (Danielson et al., 
2000) 
 
2.6.3.2   Acylation  
 
Acylation is another derivatization method that is used to convert compounds 
with active hydrogens such as (OH, NH, SH) into ester, amide, and thioester 
respectively by using a carboxylic acid or its derivative (Danielson et al., 2000). 
Acylation derivatives can be obtained as a result of the reaction between different 
functional groups such as amine, alcohol, thiols, amides, enols, phenols, 
sulfonamides, unsaturated compounds and aromatic rings with acylation reagents. 
There are three main types of reagents: acyl halides, acid anhydrides and reactive 
acyl derivatives. The most popular acyl derivatives are haloalkylacyl because of its 
role in increasing the electron affinity of compounds and create highly sensitive 
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analysis when NCI-MS is used. Other acyl derivatives which are the perfluoroacyl 
derivatives are widely used because of their advantage in having a high m/z value 
spectra; these derivatives are: trifluoroacetyl (TFA), heptafluorobutyryl (HFB) and 
pentafluoropropionyl (PFP). Acylation reactions using HFBA, PFPA and TFAA 
derivatization reagents are shown in schemes 2.2, 2.3 and 2.4 respectively.  
 
C3F7OCOCOC3F7 + H-Y-R → C3F7OC-Y-R + C3F7OC-OH                   (2.2) 
 
 C2F5OCOCOC2F5 + H-Y-R → C2F5OC-Y-R + C2F5OC-OH                  (2.3) 
 
 CF3OCOCOCF3 + H-Y-R → CF3OC-Y-R + CF3OC-OH                       (2.4)  
  
Schemes 2.2, 2.3, 2.4: Derivatization reactions using HFBA, PFPA and TFAA 
respectively: Y = O, NH, NR´, R, R´ = Alk, Ar, adapted from (Mohd, 2012) 
 
In addition to these acyl derivatives, there is what is known as 
trifluoroacetylation which can be applied to amine, hydroxyl, and thiol groups by 
using N-methylbis(trifluoroacetamide) (MBTFA) or bis(trifluoroacetamide (BTFA) 
which is characterized by high volatility and do not interfere in the GC analysis . 
There are many articles that have presented results of the use of perfluoroacyl 
derivatives in the determination of amphetamine and related drugs in urine. In 1996, 
Jon Jonsson et al published their articles that mentioned the use of trifluoroacetic 
anhydride (TFA) as a derivatising agent for the determination of amphetamine in 
authentic samples by (GC-MS) and compared the results to those that used another 
derivatising agent, the chloroformate derivatives by using Nitrogen Phosphorus 
Detector Gass Chromatograph (GC-NPD) (Jonsson et al., 1996). Another article 
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published in 2009 by Tamer Awad et al on the use of perfluoroacyl derivative 
(heptafluorobutyrlamides and pentafluoropropionylamides ) to distinguish between 
primary and secondary regioisomeric amines (3-methoxy-4-methylphenethylamines 
and 4-methoxy-3-methyl-phenethylamines); the study showed that both PFPA and 
HFBA derivatives are suitable for chromatographic separation purposes,  However, 
the HFBA derivative offered more unique fragment ions which provide additional 
distinction among the regioisomeric substances (Awad et al., 2009). In an article 
published in 2002, Huang et al proved that the combination of heptafluorobutyric 
chloride (HFBCl) and HFBA as a derivatizing reagents by using headspace solid-
phase microextraction (HS-SPME) method achieved high sensitivity for 
amphetamine and methamphetamine analysis; the use of this new acylation 
technique which is based on water hydrolysis of derivatizing reagents is because the 
amphetamines  cannot be acylated effectively in heated aqueous solution (Huang et 
al., 2002). In a research conducted in 2001,  presented the determination of the ring 
substituted amphetamines that were abused by a group of recovering opiate abusers 
participating in a methadone maintenance programme in a Dublin Drug 
Rehabilitation Centre; in this analysis the use of MBTFA as a derivatizing reagents 
for the determination of the amphetamine type stimulants (Kavanagh et al., 2001). N-
TFA-O-TMS is a derivative formation that is produced from trimethylsilylation 
reagent which is MSTFA followed by MBTFA which is a trifluoroacylating reagent. 
This derivative is used for amino acids, phenolalkylamines, and hydroxyamines 
because of its stability in solution and provides excellent chromatographic properties. 
 
 
 
